InvestorsHub Logo
Followers 60
Posts 7400
Boards Moderated 0
Alias Born 10/20/2014

Re: None

Thursday, 03/09/2023 7:43:48 AM

Thursday, March 09, 2023 7:43:48 AM

Post# of 426447
Eli Lilly's Alzheimer's drug failed its phase 3 clinical trial.
The value of the loss to LLY's stock so far around $3.5 billion.
I wonder if it would be possible to us retrospective analysis to
see if Vascepa affects the progression of AD. The Brave study
results which I expect will be positive may have value if Alex Denner
uses those results to get BP more interested in Vascepa as:
1. A CVD drug.
2. An adjunct drug for cancer.
3. A drug to slow the progression of AD.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News